First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin
Public ClinicalTrials.gov record NCT00981058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Multicenter, Open-Label Phase 3 Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab (IMC-11F8) Versus Gemcitabine-Cisplatin Chemotherapy Alone in the First-Line Treatment of Patients With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The research study is testing the investigational drug necitumumab (IMC-11F8) in the treatment of advanced non-small cell lung cancer. The aim of this study is to determine if necitumumab, given together with a standard chemotherapy combination consisting of cisplatin and gemcitabine will be more effective in improving participant disease than the standard chemotherapy combination alone.
Study identification
- NCT ID
- NCT00981058
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,093 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 7, 2010 (Actual)
- Primary completion
- Jun 17, 2013 (Actual)
- Completion
- May 30, 2024 (Actual)
- Last update posted
- Jun 18, 2025
2010 – 2024
United States locations
- U.S. sites
- 15
- U.S. states
- 15
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| ImClone Investigational Site | Chandler | Arizona | 85224 | — |
| ImClone Investigational Site | Fayetteville | Arkansas | 72703 | — |
| ImClone Investigational Site | Sacramento | California | 95816 | — |
| ImClone Investigational Site | Galesburg | Illinois | 61401 | — |
| ImClone Investigational Site | Goshen | Indiana | 46526 | — |
| ImClone Investigational Site | Wichita | Kansas | 67214 | — |
| ImClone Investigational Site | Hazard | Kentucky | 41701 | — |
| ImClone Investigational Site | Baltimore | Maryland | 21204 | — |
| ImClone Investigational Site | Jefferson City | Missouri | 65109 | — |
| ImClone Investigational Site | Lincoln | Nebraska | 68510 | — |
| ImClone Investigational Site | New York | New York | 10065 | — |
| ImClone Investigational Site | Akron | Ohio | 44304 | — |
| ImClone Investigational Site | Camp Hill | Pennsylvania | 17011 | — |
| ImClone Investigational Site | Memphis | Tennessee | 38104 | — |
| ImClone Investigational Site | Fairfax | Virginia | 22031 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 167 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00981058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 18, 2025 · Synced Oct 28, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00981058 live on ClinicalTrials.gov.